Drugs that contain Peramivir
1. List of Rapivab drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6562861 | BIOCRYST | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
Dec, 2023
(6 months from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10391075 | BIOCRYST | Antiviral treatments |
Feb, 2027
(3 years from now) | |
| US8778997 | BIOCRYST | Antiviral treatments |
May, 2027
(3 years from now) | |
Do you want to check out RAPIVAB patents from before 2022?
Market Authorisation Date: 19 December, 2014
Treatment: Treatment of acute uncomplicated influenza in patients 2 years and older; Treatment of acute uncomplicated influenza in patients 6 months and older; Treatment of acute uncomplicated influenza in adult...
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
RAPIVAB family patents
12
United States
8
Korea, Republic of
4
Australia
4
Japan
3
Mexico
2
Canada
2
Brazil
2
China
2
EA
1
New Zealand
1
South Africa
1
Malaysia
1
Hong Kong
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic